This Solicitation opportunity from Department Of Defense was posted on May 4, 2026. The submission period has ended. Browse the details below for market research, or find similar active opportunities.
DoW Breast Cancer, Breakthrough Award Level 3
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
Active Opportunities Like This One
AI Contract Overview
The Department of the Army and Defense Health Agency are soliciting applications for the Fiscal Year 2026 Breast Cancer Research Program Breakthrough Award Level 3 under solicitation HT942526BCRPBTA3. This program supports advanced translational studies with high potential to make major breakthroughs in breast cancer research. Applications must address at least one overarching FY26 BCRP challenge and identify the specific patients or at-risk individuals who would benefit. The award supports a maximum performance period of four years, with total funding caps of 5.6 million dollars for single Principal Investigator applications and 7.0 million dollars for Partnering PI Option applications. Approximately 12.6 million dollars is available to fund about two awards. Eligible applicants must be registered in SAM.gov, eBRAP.org, and Grants.gov. The research team must include at least two breast cancer consumer advocates. While not required, small-scale clinical trials such as phase 1/1b are permitted. The application process is a two-step sequence, with pre-applications due June 12, 2026, and full applications due September 30, 2026. Evaluation is conducted through a two-tier process consisting of a peer review for technical merit followed by a programmatic review for relevance to BCRP priorities. Key requirements include the disclosure of foreign affiliations for all key personnel and mandatory approval from the DHA R&D Office of Research and Regulatory Compliance for any research involving human or animal subjects.
General Info
Place of Performance
Not specifiedSet-Aside
Timeline
Submission Closed
Organization & Contact Information
Full Description
Summary: The fiscal year 2026 (FY26) Breast Cancer Research Program (BCRP) Breakthrough Award mechanism supports promising research with high potential to lead to or make breakthroughs in breast cancer. All applications must address at least one of the FY26 BCRP overarching challenges or provide adequate justification for exception. Applications must address the challenge in a way that can lead to a breakthrough and have major impact. The FY26 Breakthrough Award mechanism contains four different funding levels designed to support major (but not all) stages of research that will lead to clinical application. Each level specifies a distinct research scope. This program announcement discusses the Breakthrough Award Level 3.
Distinctive Features:
· For this funding mechanism, small-scale clinical trials are allowed but not required. Applications proposing projects with a clinical trial should be submitted under the Clinical Trial option.
· The research team must include two or more breast cancer consumer advocates.
· This funding mechanism allows for a single Principal Investigator (PI), or two partnering PIs referred to as the Initiating PI and the Partnering PI. For the Partnering PI Option (PPIO), only the Initiating PI will submit a pre-application, but both PIs will need to submit at the full application stage. Be advised, failure to submit all associated (Initiating and Partnering PI) applications by the deadline may result in administrative withdrawal.
More opportunities from Department Of Defense → Department Of The Army -- Usamraa
Same awarding agency
Find Active Opportunities Like This
Get AI-powered intelligence on the opportunities still open
Every page of the solicitation package shredded into a compliance breakdown
AI-powered matching based on your capabilities and past performance
Competitor and incumbent history on the requirement
Automated alerts on amendments, Q&A deadlines, and award
Join 750+ contractors already using CLEATUS
